MarketWatch
‘King Keytruda’s reign continues.’ Investors aren’t wowed by a promising new lung cancer drug.
The highly anticipated study found that ivonescimab reduced the risk of death by 34% compared with another drug
M
Source
MarketWatch
Read full article at MarketWatch
Opens original article in a new tab
Advertisement
